Molecular Testing Becoming Essential in AML Treatment
Amer Zeidan, MBBS, Associate Professor of Hematology, Yale School of Medicine, Yale Cancer Center, tells us about his study investigating onvansertib in combination with low-dose cytarabine or decitabine in patients with relapsed/refractory acute myeloid leukemia (AML)
Published:11 October 2019
The published content on this page is not directed by any sponsors and is at the sole discretion of Caribou Publishing and the OBR editorial staff.
© Caribou Publishing. All rights reserved. Reproduction in whole or in part is prohibited.